Cargando…
Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists
Although there is no shortage of potential drug targets, there are only a handful known low-molecular-weight inhibitors of protein-protein interactions (PPIs). One problem is that current efforts are dominated by low-yield high-throughput screening, whose rigid framework is not suitable for the dive...
Autores principales: | Koes, David, Khoury, Kareem, Huang, Yijun, Wang, Wei, Bista, Michal, Popowicz, Grzegorz M., Wolf, Siglinde, Holak, Tad A., Dömling, Alexander, Camacho, Carlos J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299697/ https://www.ncbi.nlm.nih.gov/pubmed/22427896 http://dx.doi.org/10.1371/journal.pone.0032839 |
Ejemplares similares
-
Discovery of Highly Potent p53-MDM2 Antagonists and
Structural Basis for Anti-Acute Myeloid Leukemia Activities
por: Huang, Yijun, et al.
Publicado: (2014) -
Fragment-Based Library
Generation for the Discovery
of a Peptidomimetic p53-Mdm4 Inhibitor
por: Boltjes, André, et al.
Publicado: (2014) -
Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein
por: Reyes Romero, Atilio, et al.
Publicado: (2022) -
The conserved ubiquitin-like protein Hub1 plays a critical role in splicing in human cells
por: Ammon, Tim, et al.
Publicado: (2014) -
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
por: Zak, Krzysztof M., et al.
Publicado: (2016)